Kiniksa Pharmaceuticals

HAMILTON, D0 · Founded 2015 · CIK 0001730430 · Biotech · Public

biopharmaceutical therapeutics for inflammatory and autoimmune diseases

kiniksa.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.9M
1 Form D · Apr 2019
90 months since last filing
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,949,876
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1866Regenerative Medical Solutions Inc—$7.0M
1867Angarus Therapeutics, Inc.—$6.9M
1868Evoke Pharma Inc—$6.0M
1869Kiniksa Pharmaceuticals—$5.9M
1870Jennerex, Inc.—$5.4M
1871AKTTYVA THERAPEUTICS, INC.——
1872Oncolix, Inc.—$8.9M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • FELIX BAKERDirector
  • THOMAS BEETHAMExecutive Officer
  • STEPHEN BIGGARDirector
  • G. BRADLY COLEDirector
  • CHRIS HEBERLIGExecutive Officer
  • RICHARD LEVYDirector
  • THOMAS MALLEYDirector
  • TRACEY MCCAINDirector
  • SANJ PATELDirector · Executive Officer
  • KIMBERLY POPOVITSDirector
  • BARRY QUARTDirector

Patents

USPTO · 0 granted of 6
  • TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYapplication
  • Oncostatin M Receptor Antigen Binding Proteinsapplication
  • Stable Anti-osmr Antibody Formulationapplication
  • Treatment Of Cytokine Release Syndrome With Gm-csf Antagonistsapplication
  • TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYapplication
  • Methods Of Treating Or Reducing Risk Of Transplant Rejectionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.